




OTCQX: BLEVF
CNSX: BE

CORPORATE
PRESENTATION

OCTOBER 2018

This document includes forward-looking statements within the meaning of certain securities laws, including the “safe harbour” provisions of the Securities Act (Ontario) and other provincial securities law in Canada. These forward-looking statements include, but are not limited to, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. The Company strongly cautions readers not to place undue reliance on these statements, as a number of important factors, many of which are beyond our control, could cause the Company’s actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to: general economic conditions; pending and proposed legislative or regulatory developments in Canada including the impact of changes in laws, regulations and the enforcement thereof; reliance on funding models in Canada; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensifying competition resulting from established competitors and new entrants in the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total patients and customers; technological change and obsolescence; loss of services of key senior management personnel; privacy laws; structural subordination of common shares; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company’s securities; dilution; and future sales of the Company’s securities. The foregoing list of important factors that may affect future results is not exhaustive. When reviewing the Company’s forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as required by Canadian securities law, the Company does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by the Company or on the Company’s behalf. Such statements speak only as of the date made. The forward-looking statements contained in this Document should not be relied upon as representing the view of the Company or its management as of any date subsequent to the date of this Document. Neither the Company nor its management is under any obligation, and neither undertakes, to update any of this information at any particular time. Neither the Company nor its management assumes any obligation to update or revise forward looking statements should circumstances or estimates or opinions changes. None of the Company or its affiliated or related partnerships and corporations or their respective directors, officers, partners, employees, agents or representatives makes any representation or warranty as to the accuracy or completeness of the Document or any statements, estimates or projections, and none will assume any liability for any representations (express or implied) contained in, or for any omissions from, the Document, or for any other written or oral communications transmitted to prospective investors in the course of their evaluation of the Company and its business. An investor will only be entitled to rely on those representations and warranties contained in the definitive agreement or agreements which constitute the financing. Use of this Document is restricted to parties to whom the Company delivers the Document and the recipient and its representatives shall keep confidential all information contained herein or otherwise provided in connection with the proposed financing which is not already public or which is not subsequently made public, and will use the Document only for the purpose set forth above. In addition, each recipient will not copy, reproduce or distribute the Document in whole or in part to others, at any time, without the prior express written consent of the Company.

The Foundation




**Product Development
Built on Research**

Dedicated R&D Team
focused on developing products to
capitalize on concentrates and
edibles when allowed in 2019

Proprietary extraction
and processing
techniques
(patent pending)

Collaboration with
academic institutions



**Production
Capacity**

Funded production
capacity projected to be
in excess of 150,000 kg/yr

Funded footprint
totalling 1,636,000 sq ft
of indoor and greenhouse

Industry leading yields

Facilities strategically located
across Canada and abroad



**Sales and
Distribution**

Provincial supply agreements
with access to over 55%
of the Canadian population

Strategy to capitalize on
international opportunities-
undertaking negotiations
to supply major EU markets

Diversified house of brands,
able to serve large and niche
markets alike



**Retail
Expansion**

Retail channel providing
province-wide access to the
Saskatchewan market

Pre-qualified by the Manitoba
government for retail
locations on Manitoba

Capability to offer retail at
flagship facility in
London, Ontario with further
franchise opportunities
being explored

Mutually beneficial partnerships can produce groundbreaking research and innovation that drives economic growth, solves complex problems, and creates a more skilled workforce.

**LESLEY CAMPBELL, PH.D.
RYERSON UNIVERSITY**


Dr. Lesley Campbell is a Professor in the Department of Chemistry and Biology at Ryerson University. She is an evolutionary biologist with a strong history studying weedy and invasive plant evolution and currently possesses a federally issued Industrial Hemp Research License. She has previously worked on industrial C. sativa production problems including heritability, maternal effects, phenotypic plasticity and extraction protocols.

**MOHIT BHANDARI, PH.D.
MCMASTER UNIVERSITY**

Dr. Mohit Bhandari is a world-leading researcher specializing in large international Research Chair at McMaster University, a University Scholar, and the Associate Chair of Research for Surgery. He was won numerous awards for contributions to research and evidence-based orthopaedics including the Order of Ontario, and the Kappa Delta award.

**MICHAEL ROGERS, MSC & PH.D.
GUELPH UNIVERSITY**

Michael Rogers joined the Department of Food Science in 2014 after holding faculty positions at Rutgers University and the University of Saskatchewan and as the Center Director for the Gastrointestinal Physiology Center at New Jersey's Institute of Food, Nutrition and Health. He studies molecular gels, self-assembly of nano-fibers and nanotechnology, focusing on delivery of bioactives and the biophysics of digestion. Michael is also the department's graduate coordinator for the M.Sc. thesis and Ph.D. programs.



Beleave is focused on developing technologies to produce ingredients that will form the building blocks of concentrates, edibles and topicals that will be permitted and widely consumed in 2019.



Patenting Solubility

We have filed a provisional patent for cannabis-based ingredients i.e. sugar, syrup elixir, and powder based on data obtained from the Natural Sciences and Engineering Research Council Engage grant.



Solving Bio-Availability

Across all delivery platforms we are using nano-encapsulation of the active ingredient allowing for most efficient deliver of the active ingredient, faster and more completely.



Patenting Extraction

We have filed a provisional patent for an extraction method. This Health Canada approved method delivers high purity and yields of cannabinoid compound using a highly scalable and efficient process.

Using the above technologies, we will be able to develop a wide range of cannabinoid based products; ranging from food and beverage to pharmaceuticals.

British Columbia

mid-late 2019

867,000
SQ FT



London

early 2019

600,000
SQ FT



London

early 2019

250,000
SQ FT



Hamilton

open now

14,500
SQ FT



2020 TOTAL



250,000 sq ft



600,000 sq ft



881,500 sq ft

1,731,500 sq ft



GREENHOUSE



OUTDOOR



INDOOR






Hamilton, ON

The first property in the Beleave portfolio, the Hamilton facility continues to be the hub of operations for extraction, packaging, and distribution.

GMP/ISO Certified:
Anticipated in early 2019

Certification will facilitate international distribution



London, ON

Existing greenhouse to be retrofitted with 250,000 sq ft of space on an 85 acre property.

Phase 1
Completed by Q1 2019
Greenhouse 150,000 sq ft

Phase 2
Completed by Q2 2019
Greenhouse 100,000 sq ft

Phase 3
Completed by Q2 2019
Outdoor 600,000 sq ft

Total London Capacity
Greenhouse: 18,000 kg/year
Outdoor: 36,000 kg/year




British Columbia

Ten indoor growing facilities jointly-designed by Beleave and Kannavis Biotech Corp., on a 50/50 operating expenditure and revenue partnership.

Phase 1
Completed by Q3 2019
Indoor - Abbotsford 87,600 sq ft
Indoor - Chilliwack: 87,600 sq ft

Phase 2
Completed by Q1 2020
Indoor Abbotsford 700,800 sq ft

Total BC Capacity
Indoor: 135,900kg/year



Colombia



60 Hectares

- Distribution to South America and abroad
- Will be able to produce cannabinoid oils
- Low cost of construction ~\$1/sq ft
- Cost per gram <10 cents

Europe



881,500 sq ft

- Negotiations underway to allow access to major European markets from GMP certified facilities.
- Hamilton 14,500 sq ft facility to receive GMP approval by mid Q4 2018
- BC 867,000 sq ft facility being built to equal GMP specifications.

Rapidly Accelerating both Recreational and Medicinal Distribution

Our long-term objective isn't complicated: We aspire to provide a consistent, reliable and curated product to suit the needs of every person. We have built a family of targeted brands to enable us to build loyalty and enthusiasm across the Beleave family.



Beleave

Over the next 12 months, Beleave will be leveraging our new technologies to create a suite of highly focused, proprietary medical products with high margins.



Seven Oaks

Seven Oaks is the recreational brand for Beleave and was acquired in 2018 based on its broad distribution and sales representing initial commitments of over 400 kilograms and close to \$3 million in revenue.



Medi-Green

Medi-Green network of three stores acquired in 2018 with annual profit of over \$400,000 (TBC). There are two new stores opening in London and Montreal and plans to expand beyond being executed.

COMING SOON

First recreational store will open in Saskatchewan in the coming months allowing for province-wide online sales. In addition, we have pre-qualified for retail stores in Manitoba and expect to operate at least one retail store in Ontario as the regulations allow. Further retail opportunities and partnerships across Canada will be assessed.

Medical Market


- Health Canada launched medical cannabis program in 2001
- Over 200,000 patients registered in the program, and with a 5% month-over-month growth rate in 2017 it continues to grow
- Conservative estimates from Health Canada suggest the medical market will reach 450,000 patients by 2024
- A lack of domestic production capacity in foreign medical markets presents a great export opportunity for Canadian LPs

Non-Medical Market

- Initial supply constraints are expected during the early years of legalization as Canada has one of the world's highest rates of cannabis consumption
- Recent market forecasts estimate that Canadian demand could be up to 40% higher than originally than suggested, exceeding 900,000 kgs in 2018
- Demand could potentially be driven ever higher with the inclusion of edibles in the Cannabis Act

revenue forecast

Revenue
Grams



Attributable to Beleave bottom line

2019

Total Revenues: \$185,568,750

Total Grams: 41,803,125

2020

Total Revenues: \$477,765,000

Total Grams: 99,127,500

* Based on current average wholesale price of \$5.33

** Revenues and yields are net of JV deductions

Canadian Listing - CNSX: BE
US Listing - OTCQX : BLEVF


Share Structure as of October 5,2018	Amount	Percentage
Common Shares Outstanding	59,291,313	81%
Reserved for Issuance*	14,086,721	19%
Fully Diluted Shares	73,378,034	100%
Cash Balance (as at June 30, 2018)	\$9,549,352	

*Reserved for issuance includes stock options and warrants

market comparison

Company	Market Cap (in millions)	Total Funded Footprint (sq ft)	Total Funded Capacity (kg)	Oils / Extraction	Company Clinics	Company Retail Stores	University /Research	International Operations	Revenues
Beleave	78	1,731,500	150,000	No (But soon)	Yes	Yes	Yes	Yes	Yes
Canopy Growth	14,149	5,600,000	~540,000	Yes	No	Yes	Yes	Yes	Yes
Aurora Cannabis	12,280	4,505,000	570,000	Yes	No	Yes	Yes	Yes	Yes
Aphria	3,790	●	225,000	Yes	No	No	No	Yes	Yes
Cronos Group	2,220	1,201,000	117,150	Yes	Yes	No	Yes	Yes	Yes
TGOD	1,610	1,257,245	170,000	Yes	No	No	No	Yes	No
CannTrust	1,250	1,110,000	100,000	Yes	No	No	Yes	Yes	Yes
FSD Pharma	923	~3,800,000	●	No	No	No	Yes	Yes	Yes
OrganiGram	945	480,000	110,000	Yes	Yes	No	No	Yes	Yes
TerrAscend	766	~18,000	~2000	Yes	Yes	No	No	No	Yes
Flowr	482	85,000	12,000	No	No	No	Yes	No	No
Supreme	557	342,000	50,000	No	No	No	No	Yes	Yes
Newstrike	395	320,000	25,000	No	No	Yes (Partnership)	No	No	No

As at October 5, 2018



Funded Capacity (kg/Year) as at Fall 2018

Market Landscape





Control

Inconsistent product quality and handling care across batches




Market Diversification

Consistent product quality and yield with zero production disruptions and crop failures has always been status quo at Beleave.



Differentiation

Strictly regulated environment adds new challenges to expose consumers to brands and competitive differentiators



House of Brands

Authentic brands that stand out with creative marketing, attractive packaging and memorable online and in-store buying experiences for highly targeted groups of individuals



Distribution

With supply continuing to increase rapidly and provincial monopolies controlling access to markets, companies without distribution channels will not be profitable



Vertical Supply Chain


First mover advantage with provincial distribution channels already secured providing access to over 55% of the market.

Established relationships with provincial purchasers - high margins, multiple revenue streams

Beleave is rapidly expanding its presence in all aspects of cannabis production, distribution, and sales and is gearing up for a stellar 2019 and beyond.

Beleave has, and is continuing to build, a robust distribution and sales model to capitalize on the existing medicinal and upcoming recreational markets.

Beleave is uniquely poised to capitalize on the growing cannabis industry thanks to its partnerships, investments in R&D, and proprietary knowledge that together result in a quality product and a strong, reputable brand.



Formed by nature,
perfected by science.

We're bridging science and tradition
to bring you remarkable cannabis
products.

meet the team



Andrew T. Wnek

CA, CPA, B.COMM, MBA
Chief Executive Officer, Director

Andrew offers significant retail, oil and gas, and not-for-profit industry experience translated from a robust twenty-one year career, including leading large multi-layered projects with corporate giant, Canadian Tire. His vision for Beleave is coming to fruition with a powerhouse team in motion.



Bojan Krasic

MIM
President, Chief Financial Officer,
Director

Bojan was responsible for leading strategy, business development, M&A transactions for Beleave. With well over a decade of career development, Bojan offers wide ranging financial expertise built with Thomas Weisel Partners Canada Inc., Stifel Nicolaus Canada Inc., and later serving as CEO of Terrella Capital and is a board member of public and private companies.



Bill Panagiotakopoulos

Chief Operational Officer, Director

Bill was an early mover in Canada's cannabis sector and has contributed significantly to successfully navigating the regulatory framework to obtain a cannabis production and sales license. Bill was the founder and owner of Cardinal Group Inc, specializing in evaluating opportunities and helping set strategic goals in business development.

meet the team



Roger Ferreira, Ph.D.

Chief Science Officer, Director

Roger leads Beleave's science and innovation program and offers substantial experience in laboratory management (University of Toronto & Toronto University Health Network) and his PhD training in the area of neuroimmunology.



Grant McLeod

SVP, Regulatory Affairs
General Council

Grant is a lawyer with over 14 years of government and regulatory experience. Grant has led a number of public sector organizations providing significant organizational skills and corporate governance experience to draw on. His past positions have included senior roles at the Privy Council Office, the Attorney General's Office (Ontario), and for US government implementing partners in Afghanistan. Grant is the Co-Founder of Seven Oaks, which was acquired by Beleave, and was instrumental in securing provincial supply agreements.



Mark Heselton

Director

Mark is an experienced pharmaceutical executive offering more than 25 years with Fortune 100, NYSE listed, research-based pharmaceutical companies including Bristol-Myers Squibb, Merck and Pfizer.



Mark Miles

Director

Mark is the President of M2PM Limited and has more than thirty years of expertise in the construction and development industries, and ten years dedicated to executive services for the project design, construction and delivery for a full spectrum of publicly procured infrastructure projects, including complex construction projects, including the SkyDome, Metro Hall, Sunnybrook Hospital and Princess Margaret Hospital, to name a few.

Andrew T. Wnek

CHAIRMAN & CEO

416.669.1530

ANDREW@BELEAVE.COM

Bojan Krasic

PRESIDENT & CFO

905.979.2937

BOJAN@BELEAVE.COM